Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistance
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer, predict disease risk assessment, and develop therapeutic avenues against said disease.
1 . A method for screening for efficacy of disease process modulating agents for insulin resistance comprising:
(a) providing a sample of bodily fluid containing a biopolymer marker consisting of SEQ ID NO:2;
(b) adding a quantity of said agent sufficient to interact with said biopolymer marker consisting of SEQ ID NO:2; and
(c) determining the presence of an interaction between said agent and said biopolymer marker consisting of SEQ ID NO:2;
wherein said interaction is determinative of efficacy of said disease process modulating agent.
2 . A method for diagnosing insulin resistance comprising:
(a) providing a sample; and
(b) determining a presence of a biopolymer marker consisting of SEQ ID NO:2 in said sample;
wherein the presence of said biopolymer marker consisting of SEQ ID NO:2 is diagnostic for insulin resistance.